Deepak L. Bhatt

Interventional / Structural Cardiology

Clinical Research Institute

About

Deepak L. Bhatt works in Interventional / Structural Cardiology affiliated with Clinical Research Institute.

Deepak L. Bhatt, MD, MPH, MBA is the Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai. He previously served as Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and as Professor of Medicine at Harvard Medical School. He has led or co-led multiple large cardiovascular outcomes trials in interventional cardiology, antithrombotic therapy, and lipid management.

Research focus

Percutaneous Coronary InterventionAntiplatelet TherapyAcute Coronary SyndromesLipid-Lowering TherapyCardiometabolic Outcomes in Diabetes and Heart Failure

Impact

3,635 pubs · 195,459 cites · h-index 191

Training

MD
Weill Cornell Medicine
1993
MPH
Harvard T.H. Chan School of Public Health
2008
Executive MBA
University of Oxford
2024

Affiliations

Work Experience

Director of Mount Sinai Fuster Heart Hospital and Dr. Valentin Fuster Professor of Cardiovascular Medicine

Icahn School of Medicine at Mount Sinai / Mount Sinai Health System · 2022 - Present

Executive Director of Interventional Cardiovascular Programs and Professor of Medicine

Brigham and Women’s Hospital / Harvard Medical School · 2013 - 2022

Chief of Cardiology

VA Boston Healthcare System · 2008 - 2013

Interventional Cardiologist, Associate Professor of Medicine, Director of Interventional Cardiology Fellowship

Cleveland Clinic · 2001 - 2008

Publications

Clinical Trial

NOV 2SchlossCirculation

Long-Term Outcomes of Endoscopic or Open Vein Harvesting for Coronary Artery Bypass Grafting: A 10-Year Follow-Up of the REGROUP Randomized Clinical Trial

2d ago

Level 3: Clinical Trial

SchlossCirculation

Long-Term Outcomes of Endoscopic or Open Vein Harvesting for Coronary Artery Bypass Grafting: A 10-Year Follow-Up of the REGROUP Randomized Clinical Trial

meta-analysis6 mentionsJACC Highlight

APR 2017PalmeriniJournal of the American College of Cardiology

Shorter DAPT after DES cuts bleeding-related death ~35% vs prolonged therapy, reducing overall mortality.

May heighten caution on DAPT prolongation after stenting; hypothesis-generating and leaves optimal duration open for research.

Apr 2017Open Access

JACC Highlight

Level 1: Meta-Analysis

PalmeriniJournal of the American College of Cardiology

Shorter DAPT after DES cuts bleeding-related death ~35% vs prolonged therapy, reducing overall mortality.

Implication

May heighten caution on DAPT prolongation after stenting; hypothesis-generating and leaves optimal duration open for research.

Meta-Analysis · n=15,220

OCT 13KahnUniversity of North Carolina at Chapel Hill

Tirzepatide is associated with ~28% lower MACE-3 risk versus imputed placebo in T2D and ASCVD.

Supports tirzepatide for MACE reduction; extends indirect evidence from GLP-1 agonist trials.

3w agoOpen Access

Kahn

Tirzepatide is associated with ~28% lower MACE-3 risk versus imputed placebo in T2D and ASCVD.

Implication

Supports tirzepatide for MACE reduction; extends indirect evidence from GLP-1 agonist trials.

reviewEuropean Heart Journal Highlight

OCT 28KhanEuropean Heart Journal

Mild autonomous cortisol secretion linked to ~2.5-fold higher cardiovascular mortality.

May merit cortisol assessment in resistant hypertension and difficult-to-control T2DM; leaves open whether intervention reduces cardiovascular mortality.

1w ago

European Heart Journal Highlight

Level 5: Literature Review

KhanEuropean Heart Journal

Mild autonomous cortisol secretion linked to ~2.5-fold higher cardiovascular mortality.

Implication

May merit cortisol assessment in resistant hypertension and difficult-to-control T2DM; leaves open whether intervention reduces cardiovascular mortality.

Original Research

OCT 22KoyawalaEuropean Heart Journal - Cardiovascular Pharmacotherapy

ESC Congress 2026 Antithrombotic Highlights: Balancing Ischemic and Bleeding Risk After Percutaneous Intervention

1w agoOpen Access

KoyawalaEuropean Heart Journal - Cardiovascular Pharmacotherapy

ESC Congress 2026 Antithrombotic Highlights: Balancing Ischemic and Bleeding Risk After Percutaneous Intervention

cohort · n=1,475JACC Highlight

NOV 2017SinghJournal of the American College of Cardiology

Prevention guidelines identify only ~49% of young adults as statin-eligible prior to first MI.

Guidelines miss most young adults before first MI, especially women; leaves open whether refined risk tools are needed.

Nov 2017Open Access

JACC Highlight

Level 3: Cohort Study

SinghJournal of the American College of Cardiology

Prevention guidelines identify only ~49% of young adults as statin-eligible prior to first MI.

Implication

Guidelines miss most young adults before first MI, especially women; leaves open whether refined risk tools are needed.

Guideline4 mentionsJACC Highlight

NOV 2012NewbyJournal of the American College of Cardiology

ACCF 2012 Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations

Nov 2012Open Access

JACC Highlight

Level 1: Clinical Guideline

NewbyJournal of the American College of Cardiology

ACCF 2012 Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations

Original ResearchCirculation Highlight

DEC 2015ConnellyCirculation

Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus

Dec 2015

Circulation Highlight

ConnellyCirculation

Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus

Guideline1 mentionsCirculation Highlight

DEC 2012JacobsCirculation

ACCF/AHA Clinical Practice Guideline Methodology Summit Report

Dec 2012

Circulation Highlight

Level 1: Clinical Guideline

JacobsCirculation

ACCF/AHA Clinical Practice Guideline Methodology Summit Report

Subodh Verma

Cardiac surgeon-scientist, St. Michael's Hospital, University of Toronto · St. Michael's Hospital, University of Toronto

12d

The adipokine hypothesis of Packer represents a landmark conceptual advance in the evolving landscape of HFpEF research. […] Whether this adipose-centric model will be a reliable guidepost for therapeutic decision-making remains uncertain. What is certain is that it will shape future investigation and challenge us to reconsider longstanding assumptions about this complex syndrome.

Parsing the Adipokine Axis in HFpEF

Journal of the American College of CardiologyVerma et al.Oct 2025

Risk Assessment10 mentionsCirculation Highlight

JAN 2018JollyCirculation

Risks of Overinterpreting Interim Data

Jan 2018Open Access

Circulation Highlight

Level 4: Risk Assessment

JollyCirculation

Risks of Overinterpreting Interim Data

Guideline8 mentionsJACC Highlight

OCT 2019ShapiroJournal of the American College of Cardiology

Preventive Cardiology as a Subspecialty of Cardiovascular Medicine

May prompt new preventive cardiology fellowships; leaves open optimal integration with cardiometabolic medicine pathways.

Oct 2019Open Access

JACC Highlight

Level 1: Clinical Guideline

ShapiroJournal of the American College of Cardiology

Preventive Cardiology as a Subspecialty of Cardiovascular Medicine

Implication

May prompt new preventive cardiology fellowships; leaves open optimal integration with cardiometabolic medicine pathways.

Christoph Bode

Cardiologist, University Heart Center Freiburg

Coronary bypass graft failure, however, was not affected

Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion

Journal of the American College of CardiologyLamy et al.Jan 2019

cohort · n=1,548JACC Highlight

MAR 2025BeerkensJournal of the American College of Cardiology

High atherogenic index of plasma trajectories show no association with post-TAVR MACCEs.

AIP trajectories should not guide post-TAVR risk stratification; leaves open metabolic phenotype effects in prospective studies.

Mar 2025Open Access

JACC Highlight

Level 3: Cohort Study

BeerkensJournal of the American College of Cardiology

High atherogenic index of plasma trajectories show no association with post-TAVR MACCEs.

Implication

AIP trajectories should not guide post-TAVR risk stratification; leaves open metabolic phenotype effects in prospective studies.

cohort · n=74,897

AUG 2025HallerJournal of the American College of Cardiology

High heart failure polygenic risk score linked to ~5-fold higher rate of new-onset HF.

HF polygenic risk score was associated with incident heart failure; leaves open whether it improves clinical risk stratification or prevention.

PDF

Aug 2025Open Access

Level 3: Cohort Study

HallerJournal of the American College of Cardiology

High heart failure polygenic risk score linked to ~5-fold higher rate of new-onset HF.

Implication

HF polygenic risk score was associated with incident heart failure; leaves open whether it improves clinical risk stratification or prevention.

PDF

Stephen J. Nicholls

Director, Monash Victorian Heart Institute, Monash University · Monash University

I think the take-home message is that this is a useful therapeutic in the clinic. It has favorable effects on a range of metabolic parameters which are superior to GLP-1 receptor agonists. It looks like it's at least as good in terms of atherosclerotic events; if you look at heart failure events combined, there's a more favorable effect.

Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis

European Journal of Preventive CardiologyNicholls et al.Sep 2026

Original Research

SEP 1ZhangThe American Journal of Cardiology

Sotagliflozin adds ~0.39 QALYs versus placebo with an ICER of $75,510 per QALY gained.

May support coverage at modeled pricing in T2D with worsening HF; extends SOLOIST-WHF via simulation but leaves real-world adoption open.

9w ago

ZhangThe American Journal of Cardiology

Sotagliflozin adds ~0.39 QALYs versus placebo with an ICER of $75,510 per QALY gained.

Implication

May support coverage at modeled pricing in T2D with worsening HF; extends SOLOIST-WHF via simulation but leaves real-world adoption open.

Meta-Analysis

JUL 30MannHeart Lung and Circulation

Associations Between Central Adiposity Measures and Subclinical Coronary Artery Calcification and Progression of Disease: A Collaborative Meta-Analysis of 49 Cohorts and 68,629 Participants

PDF

13w agoOpen Access

Level 1: Meta-Analysis

MannHeart Lung and Circulation

Associations Between Central Adiposity Measures and Subclinical Coronary Artery Calcification and Progression of Disease: A Collaborative Meta-Analysis of 49 Cohorts and 68,629 Participants

PDF

Original Research

AUG 1RehmanAtherosclerosis

Risk-Weighted Apob Outperforms Traditional Lipid Biomarkers in Predicting Residual Cardiovascular Risk in Statin-Treated Hypertriglyceridemic Patients: Post Hoc Analysis of the Reduce-It Placebo Arm

13w ago

RehmanAtherosclerosis

Risk-Weighted Apob Outperforms Traditional Lipid Biomarkers in Predicting Residual Cardiovascular Risk in Statin-Treated Hypertriglyceridemic Patients: Post Hoc Analysis of the Reduce-It Placebo Arm

cohort · n=61,160

JUL 28LuEuropean Journal of Heart Failure

Target-dose ACE inhibitors show no mortality benefit over below-target doses in HFpEF.

Target-dose ACE inhibitors were associated with lower kidney failure risk but no mortality benefit in HFpEF; leaves open optimal dosing pending randomized trials.

14w ago

Level 3: Cohort Study

LuEuropean Journal of Heart Failure

Target-dose ACE inhibitors show no mortality benefit over below-target doses in HFpEF.

Implication

Target-dose ACE inhibitors were associated with lower kidney failure risk but no mortality benefit in HFpEF; leaves open optimal dosing pending randomized trials.

All publications →